Nivolumab Plus Trastuzumab Deruxtecan Provides No Perceptible Clinical Benefit Over ADC Alone in Advanced HER2+ Breast Cancer

Via Peters

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. The addition of nivolumab (Opdivo) to fam-trastuzumab deruxtecan-nxki (Enhertu) did not result in a marked clinical benefit in patients with locally advanced unresectable or […]

Trastuzumab Deruxtecan Yields Clinically Meaningful Outcomes in HER2-Low Metastatic Breast Cancer

Via Peters

Patients with HER2-low metastatic breast cancer achieved clinically meaningful improvement in progression-free survival following treatment with fam-trastuzumab deruxtecan-nxki. Treatment with fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) yielded clinically meaningful improvements in key outcome measures for patients with HER2-low unresectable or metastatic breast cancer compared with investigator’s choice of chemotherapy, according to findings […]

Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer

Via Peters

SAN ANTONIO — A headline-making antibody-drug conjugate (ADC) continued to impress breast cancer specialists by demonstrating activity in tumors with low HER2 expression and in some breast cancers with undetectable HER2. As expected, trastuzumab deruxtecan (T-DXd, Enhertu) showed robust activity in HER2-overexpressing metastatic breast cancer, producing objective responses in 71% […]